Generic Name: Ketoconazole
VA Class: AM700
CAS Number: 65277-42-1
AUDIENCE: Dermatology, Family Practice, Pharmacy, Patient
ISSUE: FDA is warning health care professionals to avoid prescribing the antifungal medicine ketoconazole oral tablets to treat skin and nail fungal infections. Use of this medication carries the risk of serious liver damage, adrenal gland problems, and harmful interactions with other medicines that outweigh its benefit in treating these conditions, which are not approved uses of the drug.
FDA approved label changes for oral ketoconazole tablets in 2013 to reflect these serious risks and to remove the indications for treatment of skin and nail fungal infections. However, an FDA safety review found that oral ketoconazole continues to be prescribed for these types of conditions. Since the 2013 labeling change, one patient death has been reported to the FDA due to liver failure associated with oral ketoconazole prescribed to treat a fungal infection of the nails. See the full MedWatch Communication at for further information.
BACKGROUND:Ketoconazole in tablet form is indicated to treat serious infections caused by fungi and should be used only when other effective therapy is not available or tolerated. It works by killing the fungus or preventing it from growing. The topical forms of ketoconazole that are applied to the skin or nails have not been associated with liver damage, adrenal problems, or drug interactions.
In a July 2013 Drug Safety Communication, FDA warned that ketoconazole tablets should not be used as a first-line treatment for any fungal infection because it can cause severe liver injury and adrenal gland problems, and advised it can lead to harmful interactions with other medicines. FDA determined that the risks outweigh the benefits for treating skin and nail fungal infections and approved label changes removing this indication from the drug label and limited its labeled indication to treating only serious fungal infections.
RECOMMENDATION:Health care professionals should use ketoconazole tablets only to treat serious fungal infections when no other antifungal therapies are available. Skin and nail fungal infections in otherwise healthy persons are not life-threatening, and so the risks associated with oral ketoconazole outweigh the benefits. Other treatment options are available over-the-counter and by prescription, but are also associated with risks that should be weighed against their benefits.
Patients should discuss with their health care professionals the risks and benefits of available therapies before using any medicine to treat skin and nail fungal infections. Patients taking ketoconazole tablets should seek medical attention right away if they experience any of these signs and symptoms of liver problems, which include loss of appetite, nausea, vomiting, or abdominal discomfort; yellowing of the skin or the whites of the eyes (jaundice); unusual darkening of the urine or lightening of the stools; or pain and discomfort in the right upper abdomen where the liver is located.
For more information visit the FDA website at: and .
Serious hepatotoxicity has occurred in patients receiving oral ketoconazole, including cases that were fatal or required liver transplantation.263 384 Inform patients of the risk and monitor closely.263 384 (See Hepatotoxicity under Cautions.)
Concomitant use with certain drugs (cisapride, dofetilide, pimozide, quinidine) contraindicated because increased plasma concentrations of these drugs may occur and can lead to QT interval prolongation, sometimes resulting in life-threatening ventricular tachyarrhythmias such as torsades de pointes.263 384 (See Interactions.)
Uses for Nizoral
Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.
Alternative for treatment of blastomycosis caused by Blastomyces dermatitidis.220 234 263 288 291 292 299 300 384 424 Use only when other effective antifungals not available or not tolerated and potential benefits of oral ketoconazole outweigh potential risks.263 384
Drugs of choice are IV amphotericin B or oral itraconazole;288 292 296 297 298 299 332 333 424 436 oral fluconazole is an alternative.288 292 297 299 436 424 Ketoconazole has been used as an alternative,424 but may be less effective.424
Do not use to treat fungal infections that involve the CNS, including cerebral blastomycosis; ketoconazole CSF concentrations unpredictable following oral administration and treatment failures or relapses reported.192 263 288 295 384
Has been used for treatment of certain Candida infections† (e.g., oropharyngeal and/or esophageal candidiasis, vulvovaginal candidiasis, candiduria, chronic mucocutaneous candidiasis);292 320 322 323 328 334 no longer recommended and no longer labeled by FDA for Candida infections.263 384
Alternative for treatment of chromomycosis (chromoblastomycosis) caused by Phialophora;263 288 335 384 a response may not be attained in those with more extensive disease.335 Use only when other effective antifungals not available or not tolerated and potential benefits of oral ketoconazole outweigh potential risks.263 384
Alternative for treatment of coccidioidomycosis caused by Coccidioides immitis.263 280 292 293 303 304 305 384 426 Use only when other effective antifungals not available or not tolerated and potential benefits of oral ketoconazole outweigh potential risks.263 384
Drugs of choice for initial treatment of symptomatic pulmonary, chronic fibrocavitary, or disseminated coccidioidomycosis are oral fluconazole or oral itraconazole;426 436 440 441 IV amphotericin B recommended as an alternative and preferred for initial treatment of severely ill patients who have hypoxia or rapidly progressing disease, for immunocompromised patients, or when azole antifungals cannot be used (e.g., pregnant women).280 288 292 294 302 303 426 436 440 441
Do not use to treat fungal infections that involve the CNS, including coccidioidal meningitis; ketoconazole CSF concentrations unpredictable following oral administration and treatment failures or relapses reported.263 288 302 384
Alternative for treatment of histoplasmosis caused by Histoplasma capsulatum.234 263 288 291 292 293 384 428 Use only when other effective antifungals not available or not tolerated and potential benefits of oral ketoconazole outweigh potential risks.263 384
Drugs of choice are IV amphotericin B or oral itraconazole428 436 440 IV amphotericin B preferred for initial treatment of severe, life-threatening infections, especially in immunocompromised patients (including HIV-infected patients).428 436 440 Other azoles (fluconazole, ketoconazole, posaconazole, voriconazole) considered second-line alternatives to oral itraconazole.428 436
Alternative for treatment of paracoccidioidomycosis (South American blastomycosis) caused by Paracoccidioides brasiliensis.263 288 291 311 335 384 436 Use only when other effective antifungals not available or not tolerated and potential benefits of oral ketoconazole outweigh potential risks.263 384
Drug of choice for initial treatment of severe paracoccidioidomycosis is IV; amphotericin B.288 291 293 310 311 335 436 Oral itraconazole is drug of choice for less severe or localized infections and for follow-up therapy of severe infections after response has been obtained with IV amphotericin B.288 291 335 436
Has been used for treatment of sporotrichosis† caused by Sporothrix schenckii.312 313 335 429 Not recommended since it is less effective and associated with more adverse effects than some other azoles.429 Oral itraconazole is drug of choice for treatment of cutaneous, lymphocutaneous, or mild pulmonary or osteoarticular sporotrichosis and for follow-up therapy in more severe infections after a response has been obtained with IV amphotericin B.429
Has been used orally for treatment of dermatophyte infections† (e.g., tinea capitis†, tinea corporis†, tinea pedis†, tinea unguium† [onychomycosis]†);291 324 325 no longer recommended and no longer labeled by FDA for these infections.263 384
Has been used in conjunction with a topical anti-infective (e.g., miconazole, neomycin, metronidazole, propamidine isethionate) in the treatment of >Acanthamoeba keratitis†.134 135 136 137 138 139 140 225 Optimum therapy for Acanthamoeba keratitis remains to be clearly established, but prolonged local and systemic therapy with multiple anti-infectives and often surgical treatment (e.g., penetrating keratoplasty) usually required.134 135 136 137 138 139 140
A regimen of oral ketoconazole, rifampin, and co-trimoxazole has been used for treatment of chronic Acanthamoeba meningitis† in several immunocompetent children.187 442 (See Meningitis and Other CNS Infections under Cautions.)
Because of ketoconazole’s ability to inhibit testicular and adrenal steroid synthesis, the drug has been used in the treatment of advanced prostatic carcinoma†.106 107 108 151 179 180 181 182 183 184 284 285 286 368 369 Safety and efficacy not established and not labeled by FDA for this use.263 384
Has been used effectively for palliative treatment of Cushing’s syndrome† (hypercortisolism), including adrenocortical hyperfunction associated with adrenal or pituitary adenoma or ectopic corticotropin-secreting tumors.112 113 114 151 154 224 342 Safety and efficacy not established and not labeled by FDA for this use.263 384
Has been used with some success for treatment of hypercalcemia in adults with sarcoidosis†.363 364 365 366 394 395 Has reduced serum calcium concentrations in some, but not all, patients with sarcoidosis-associated hypercalcemia;364 365 366 394 395 hypercalcemia and increased serum 1,25-dihydroxyvitamin D concentrations may recur when ketoconazole dosage is decreased or the drug discontinued.365 366 Considered an alternative in patients who fail to respond to or cannot tolerate corticosteroids.363 365 393 394 395
Hirsutism and Precocious Puberty
Nizoral Dosage and Administration
To ensure absorption in patients with achlorhydria (see Absorption under Pharmacokinetics), some clinicians suggest administering each 200 mg of ketoconazole with an acidic beverage (e.g., Coca-Cola, Pepsi) or dissolving the dose in 60 mL of citrus juice; however, this strategy may not be adequate in all patients with achlorhydria and patients should be monitored closely for therapeutic failure.273
Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.
General Pediatric Dosage
Treatment of Fungal InfectionsOral
General Adult Dosage
Treatment of Fungal InfectionsOral
Initial dosage of 400 mg daily; if response is inadequate, some clinicians suggest dosage may be increased to 800 mg daily.220 234 288 424 Dosage of 400–800 mg daily has been used as follow-up after a response was obtained with IV amphotericin B.296 Usual duration of treatment is 6–12 months.424
200–400 mg daily.335
HIV-infected patients adequately treated for coccidioidomycosis should receive long-term suppressive or maintenance therapy (secondary prophylaxis) with oral itraconazole or oral fluconazole to prevent relapse.440
Usually treated for 6–12 weeks; more prolonged treatment (at least 12 months) may be necessary for chronic cavitary pulmonary disease or disseminated histoplasmosis.428
HIV-infected patients adequately treated for histoplasmosis should receive long-term suppressive or maintenance therapy (secondary prophylaxis) with oral itraconazole to prevent relapse.440
200–400 mg once daily.335
400 mg every 8 hours has been used for treatment of prostatic carcinoma†106 108 180 181 182 183 285 or as an adjunct in the management of disseminated intravascular coagulation (DIC) associated with prostatic carcinoma†.152 178 Risk of depressed adrenocortical function at this high dosage should be considered.263 (See Endocrine and Metabolic Effects under Cautions.)
Cautions for Nizoral
Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.
Concomitant use with certain drugs metabolized by CYP3A4 (e.g., alprazolam, oral midazolam, oral triazolam, eplerenone, ergot alkaloids, lovastatin, simvastatin, nisoldipine); increased plasma concentrations of these drugs may occur and increase or prolong their therapeutic and/or adverse effects.263 384 (See Interactions.)
Concomitant use with certain drugs (e.g., cisapride, dofetilide, pimozide, quinidine); increased plasma concentrations of these drugs may occur and can lead to QT interval prolongation, sometimes resulting in life-threatening ventricular tachyarrhythmias such as torsades de pointes.263 384 (See Interactions.)
Serious Adverse Effects
Serious adverse effects (e.g., hepatotoxicity, adrenal insufficiency) and drug interactions have been reported with oral ketoconazole.263 384 Use only when other effective antifungals not available or not tolerated and potential benefits of oral ketoconazole outweigh potential risks.263 384
Symptomatic hepatotoxicity usually apparent within first few months of ketoconazole therapy,50 61 164 167 168 169 170 188 189 190 191 263 384 but occasionally may be apparent within first week of therapy.164 166 167 191 263 384 Although ketoconazole-induced hepatotoxicity usually reversible following discontinuance of the drug,50 164 165 166 167 188 189 190 191 263 384 recovery may take several months;164 165 167 188 190 263 384 rarely, death has occurred.164 165 167 168 169 170 191 193 263 384
Ketoconazole-induced hepatotoxicity has been reported in patients who had no obvious risk factors for liver disease.263 384 Some cases reported in patients receiving high oral ketoconazole dosage for short treatment durations; others reported in those receiving low oral dosage for long durations.263 384 Many cases were reported in patients receiving the drug for tinea unguium (onychomycosis)†50 167 168 169 188 189 190 191 193 263 384 or chronic, refractory dermatophytoses†.167 191
Prior to initiation of oral ketoconazole, perform liver function tests, including serum AST, ALT, alkaline phosphatase, γ-glutamyltransferase (γ-glutamyltranspeptidase, GGT, GGTP), and total bilirubin, as well as PT, INR, and tests for viral hepatitides.164 166 167 169 170 188 189 190 193 263 384
During ketoconazole therapy, monitor serum ALT concentrations weekly.263 384 Prompt recognition of liver injury is essential.263 384 If ALT increases above ULN or 30% above baseline or if patient develops symptoms, interrupt ketoconazole therapy and perform full set of liver tests.263 384 Repeat liver tests to ensure that values normalize.263 384
Minor, asymptomatic elevations in liver function test results may return to pretreatment concentrations during continued ketoconazole therapy.164 167 191 193 If oral ketoconazole is restarted, monitor patient frequently to detect any recurring liver injury; hepatotoxicity has occurred following reinitiation of the drug (rechallenge).263 384
Endocrine and Metabolic Effects
Decreased adrenal corticosteroid secretion reported with ketoconazole dosage ≥400 mg.263 384 Can inhibit cortisol synthesis, particularly in patients receiving relatively high daily dosage or divided daily dosing.109 112 113 114 151 154 156 157 158 159 166 173 229 230 The adrenocortical response to corticotropin (ACTH) may be at least transiently diminished and a reduction in urinary free and serum cortisol concentrations may occur.109 110 112 113 114 151 154 156 157 158 159 166 173 Adrenocortical insufficiency reported rarely.109 159 160 166 173 229
In 350 patients receiving high-dose ketoconazole (1.2 g daily) for metastatic prostatic carcinoma, 11 deaths occurred within 2 weeks after initiation of the drug.263 384 These patients had serious underlying disease; not possible to ascertain from available information whether these deaths were related to ketoconazole or adrenocortical insufficiency.263 384
Gynecomastia reported in patients receiving ketoconazole.263 384 The drug can inhibit testosterone synthesis and transient decreases in serum testosterone may occur;109 110 151 174 263 384 concentrations usually return to baseline values after the drug discontinued.263 384 Ketoconazole dosages of 800 mg daily decrease serum testosterone levels; clinical manifestations of these decreased levels may include gynecomastia, impotence, and oligospermia.263 384
Other hypersensitivity reactions, including anaphylactoid reaction, erythema multiforme, rash, dermatitis, erythema, urticaria, and pruritus, have occurred.263 384 Acute generalized exanthematous pustulosis, photosensitivity, angioneurotic edema, alopecia, and xeroderma also reported.263 384
Meningitis and Other CNS Infections
Because CSF concentrations of ketoconazole are unpredictable following oral administration and because treatment failures or relapses have been reported, do not use to treat fungal infections that involve the CNS, including cerebral blastomycosis or coccidioidal meningitis.192 263 288 291 295 302 306 384 384
Not systematically studied in children of any age.263 384 Has been used in a limited number of children >2 years of age;263 384 essentially no information available on use in children <2 years of age.263 384
Common Adverse Effects
Interactions for Nizoral
Drugs Metabolized by Hepatic Microsomal Enzymes
Potential pharmacokinetic interaction with drugs metabolized by CYP3A4; possible increased concentrations of the concomitant drug and increased or prolonged therapeutic and/or adverse effects associated with the drugs.263 384
Drugs Affecting Hepatic Microsomal Enzymes
Drugs that Prolong the QT Interval
Potential interaction with drugs that are CYP3A4 substrates that prolong the QT interval; possible increased concentrations of the concomitantly administered CYP3A4 substrate which can lead to QT interval prolongation, sometimes resulting in life-threatening ventricular dysarrhythmias such as torsades de pointes.263 384 Concomitant use with these drugs contraindicated.263 384
Disulfiram reactions (flushing, rash, peripheral edema, nausea, headache) have occurred rarely in patients who ingested alcohol while receiving ketoconazole;263 267 268 384 usually resolved within a few hours263 384
Anticoagulants, oral (warfarin)
Anticonvulsants (carbamazepine, phenytoin)
Antidiabetic agents, sulfonylureas
Mefloquine: Do not use ketoconazole concomitantly with mefloquine or within 15 weeks after last mefloquine dose446
Quinine: Dosage adjustment of quinine not required; monitor closely for quinine-associated adverse effects447
Quinine: Increased quinine AUC and decreased quinine clearance447
Mefloquine: Do not use ketoconazole concomitantly with mefloquine or within 15 weeks after last mefloquine dose446
Quinine: Dosage adjustment of quinine not required; monitor closely for quinine-associated adverse effects447
Antimycobacterials (rifabutin, rifampin, isoniazid)
Antiretrovirals, HIV entry inhibitors
Maraviroc: Possible increased maraviroc concentrations200
Maraviroc: Reduce maraviroc dosage to 150 mg twice daily200
Antiretrovirals, HIV protease inhibitors (PIs)
Possible pharmacokinetic interactions if ketoconazole used in patients receiving PIs (e.g., ritonavir-boosted darunavir, fosamprenavir [with or without low-dose ritonavir], indinavir, lopinavir/ritonavir, nelfinavir, ritonavir-boosted saquinavir, ritonavir-boosted tipranavir);204 205 206 207 208 210 211 altered concentrations of the PI and/or the antifungal204 205 206 207 208 210 211
Ritonavir-boosted darunavir: Do not exceed ketoconazole dosage of 200 mg daily204
Fosamprenavir (without low-dose ritonavir): May need decreased ketoconazole dosage in those receiving >400 mg of ketoconazole daily
Indinavir (without low-dose ritonavir): Use indinavir dosage of 600 mg every 8 hours206
Lopinavir/ritonavir: Do not exceed ketoconazole dosage of 200 mg daily207
Ritonavir-boosted saquinavir: Do not exceed ketoconazole dosage of 200 mg daily210
Ritonavir-boosted tipranavir: Use concomitantly with caution; do not exceed ketoconazole dosage of 200 mg daily211
Antiretrovirals, nonnucleoside reverse transcriptase inhibitors (NNRTIs)
Delavirdine: Possible increased delavirdine concentrations212
Efavirenz: Possible decreased ketoconazole concentrations213
Etravirine: Possible increased etravirine concentrations and decreased ketoconazole concentrations214
Nevirapine: Possible decreased ketoconazole concentrations and decreased efficacy of the antifungal263
Rilpivirine: Increased rilpivirine concentrations and AUC; decreased ketoconazole concentrations and AUC226
Etravirine: Dosage adjustment of ketoconazole may be needed depending on other concomitantly administered drugs214
Nevirapine: Concomitant use not recommended263
Benzodiazepines (alprazolam, midazolam, triazolam)
Alprazolam, midazolam, triazolam: Increased benzodiazepine concentrations; possible prolonged sedative and hypnotic effects, especially in those receiving repeated or chronic therapy with the drugs263 384
HCV protease inhibitors
Boceprevir: Increased boceprevir concentrations and AUC; possible increased ketoconazole concentrations444
Telaprevir: Increased concentrations and AUCs of both drugs443
Boceprevir: If concomitant use required, do not exceed ketoconazole dosage of 200 mg daily444
Telaprevir: If concomitant use required, do not exceed ketoconazole dosage of 200 mg daily443
Histamine H2-receptor antagonists (e.g., cimetidine, ranitidine)
HMG-CoA reductase inhibitors (statins)
Immunosuppressive agents (cyclosporine, sirolimus, tacrolimus)
Cyclosporine: Careful monitoring, with possible dosage adjustment, recommended;263 384 monitor renal function and cyclosporine concentrations;146 consider reduced cyclosporine dosage or use of another immunosuppressive agent;146 patients stabilized on both drugs may require an increase in cyclosporine dosage when ketoconazole discontinued146
In vitro evidence that ketoconazole can inhibit metabolism of paclitaxel269
Clinical importance unclear; use concomitantly with caution269
Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil)
Sildenafil: Manufacturer of ketoconazole recommends that initial dose of sildenafil be reduced by 50%;263 384 manufacturer of sildenafil recommends initial sildenafil dosage of 25 mg in those receiving ketoconazole445
Tadalafil: Patients receiving ketoconazole should receive no more than 10 mg of tadalafil once every 72 hours;378 if a once-daily tadalafil regimen is used, those receiving ketoconazole should receive no more than 2.5 mg of tadalafil once daily378
Vardenafil: Patients receiving ketoconazole 400 mg daily should receive no more than a single 2.5-mg dose of vardenafil in a 24-hour period; those receiving ketoconazole 200 mg daily should receive no more than a single 5-mg dose of vardenafil in a 24-hour period379
Possible decreased absorption of ketoconazole362
Pending further accumulation of data, monitor theophylline concentrations and adjust theophylline dosage if necessary when ketoconazole is initiated or discontinued in patients receiving theophylline147
Possible substantially increased plasma trazodone concentrations and potential for adverse effects380
Consider reducing trazodone dosage in patients receiving ketoconazole380
Ketoconazole must be dissolved in gastric secretions and converted to the hydrochloride salt prior to absorption from the stomach.a Bioavailability depends on the pH of the gastric contents in the stomach; an increase in pH results in decreased absorption of the drug.a (See Absorption: Special Populations.)
Effect of food on rate and extent of GI absorption of ketoconazole has not been clearly determined.162
Considerable interindividual variations in peak plasma concentrations and AUCs have been reported.a
Oral bioavailability may be decreased in patients with achlorhydria,a including those with HIV-associated gastric hypochlorhydria.198 Concomitant administration of an acidic beverage may increase bioavailability in some individuals.273 (See Oral Administration under Dosage and Administration.)
Distributed into urine, bile, saliva, sebum, cerumen, and synovial fluid.a
May be distributed into CSF following oral administration, but CNS penetration is unpredictable and has generally been considered to be minimal.a
Plasma Protein Binding
Partially metabolized in the liver to several inactive metabolites by oxidation and degradation of the imidazole and piperazine rings, by oxidative O-dealkylation, and by aromatic hydroxylation.a
Major route of elimination of ketoconazole and its metabolites appears to be excretion into the feces via the bile.a
In fasting adults with normal renal function, approximately 57% of a single 200-mg oral dose is excreted in feces within 4 days (20–65% of this is unchanged drug); approximately 13% of the dose is excreted in urine within 4 days (2–4% of this is unchanged drug).a
Plasma concentrations and half-life not substantially affected by renal or hepatic impairment.a
Actions and Spectrum
Presumably exerts its antifungal activity by altering cellular membranes resulting in increased membrane permeability, leakage of essential elements (e.g., amino acids, potassium), and impaired uptake of precursor molecules (e.g., purine and pyrimidine precursors to DNA).127 128 130 131 Inhibits cytochrome P-450 14-α-desmethylase in susceptible fungi, which leads to accumulation of C-14 methylated sterols (e.g., lanosterol) and decreased concentrations of ergosterol.128 129 130 151
Spectrum of antifungal activity includes many fungi, including yeasts and dermatophytes.263 384 a Has some in vitro activity against some gram-positive bacteria (e.g., staphylococci, Nocardia) and some protozoa (e.g., Acanthamoeba, Leishmania).134 135 136 a
Candida: Active in vitro and in vivo against C. albicans,120 121 122 123 124 373 C. dubliniensis,283 and some strains of C. glabrata,120 122 123 124 373 C. lusitaniae,289 C. parapsilosis,373 and C. tropicalis.373
Other fungi: Active against Blastomyces dermatitidis,263 371 384 Coccidioides immitis,263 384 Cryptococcus neoformans,263 373 384 Histoplasma capsulatum,263 384 Paracoccidioides brasiliensis,263 384 Penicillium marneffei,389 390 and Phialophoa.263 384 Also active against Actinomadura madurae, Aspergillus flavus,120 122 124 A. fumigatus,122 124 Malassezia furfur (Pityrosporum orbiculare),a Petriellidium boydii,120 122 and Sporothrix schenckii.120 122 124 May be active against some strains of Exophiala castellanii275 and Scopulariopsis, including some strains of S. acremonium and S. brevicaulis.374
Ketoconazole-resistant Candida may be cross-resistant to other azole antifungals (e.g., fluconazole, itraconazole).337
In vitro and in vivo studies indicate ketoconazole can directly inhibit synthesis of adrenal steroids and testosterone.109 110 112 113 114 115 116 117 148 151 154 156 157 158 159 160 161 171 172 173 174 175 176 Appears to inhibit steroid synthesis principally by blocking several P-450 enzyme systems (e.g., 11β-hydroxylase, C-17,20-lyase, cholesterol side-chain cleavage enzyme).112 114 117 151 152 154 155 157 158 159 171 172 173 174 175 176 201
Inhibits cortisol synthesis in a dose-dependent manner in individuals with normal adrenocortical function and in patients with Cushing’s syndrome (hypercortisolism).109 112 113 114 151 154 156 157 158 159 166 173
Advice to Patients
Advise patients that oral ketoconazole is used only for treatment of certain serious fungal infections and is prescribed only when other effective antifungals not available or not tolerated and potential benefits of the drug outweigh potential risks.263 384
Risk of hepatotoxicity; importance of reporting any signs or symptoms of possible hepatic dysfunction (e.g., unusual fatigue, anorexia, nausea and/or vomiting, abdominal pain, jaundice, dark urine, pale feces) to their clinician.167 168 188 189 263 384
Risk of QT interval prolongation, especially if certain medications are used concomitantly.263 384 Importance of informing their clinicians if they have had an abnormal ECG or have a family member with a history of congenital long QT syndrome.263 384 Importance of contacting their clinicians if symptoms of QT interval prolongation occur (e.g., feeling faint, lightheaded, dizzy, irregular or fast heart beat).263 384
Risk of adrenal insufficiency if high dosage is used.263 384 Importance of informing their clinicians if they have a history of adrenal insufficiency.263 384 Importance of contacting their clinicians if symptoms of adrenal insufficiency occur (e.g., tiredness, weakness, dizziness, nausea, vomiting).263 384
Risk of hypersensitivity reactions.263 384 Importance of discontinuing ketoconazole and immediately contacting their clinicians if signs of an allergic reaction occur (e.g., rash, itching, hives, fever, swelling of lips or tongue, chest pain, trouble breathing).263 384
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
AHFS DI Essentials. © Copyright, 2016, American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814. Review Date: September 06, 2016.
Only references cited for selected revisions after 1984 are available electronically.
50. Heiberg JK, Svejgaard E. Toxic hepatitis during ketoconazole treatment. BMJ. 1981; 283:825-6. [IDIS 138588] [PubMed 6271328]
61. Firebrace DAJ. Hepatitis and ketoconazole therapy. BMJ. 1981; 283:1058-9. [IDIS 139321] [PubMed 6271330]
101. Craven PC, Graybill JR, Jorgensen JH et al. High-dose ketoconazole for treatment of fungal infections of the central nervous system. Ann Intern Med. 1983; 98:160-7. [IDIS 164926] [PubMed 6297345]
102. van Dijke CPH, Veerman FR, Haverkamp HCH. Anaphylactic reactions to ketoconazole. BMJ. 1983; 287:1673.
103. Meunier-Carpentier F. Chemoprophylaxis of fungal infections. Am J Med. 1984; 76:652-6. [IDIS 183885] [PubMed 6324589]
104. Jones PG, Kauffman CA, McAuliffe LS et al. Efficacy of ketoconazole v nystatin in prevention of fungal infections in neutropenic patients. Arch Intern Med. 1984; 144:549-51. [IDIS 182148] [PubMed 6322710]
105. Meunier-Carpentier F. Treatment of mycoses in cancer patients. Am J Med. 1983; 74(Suppl.):74-9. [IDIS 165059] [PubMed 6295156]
106. Trachtenberg J, Pont A. Ketoconazole therapy for advanced prostate cancer. Lancet. 1984; 2:433-5. [IDIS 189398] [PubMed 6147504]
107. Allen JM, Kerle DJ, Ware H et al. Combined treatment with ketoconazole and luteinising hormone releasing hormone analogue: a novel approach to resistant progressive prostatic cancer. BMJ. 1983; 287:1766. [IDIS 179861] [PubMed 6315133]
108. Williams G. Ketoconazole for prostate cancer. Lancet. 1984; 2:696. [IDIS 190420] [PubMed 6147719]
109. Pont A, Graybill JR, Craven PC et al. High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med. 1984; 144:2150-3. [IDIS 192651] [PubMed 6093722]
110. Pont A, Williams PL, Azhar S et al. Ketoconazole blocks testosterone synthesis. Arch Intern Med. 1982; 142:2137-40. [IDIS 160960] [PubMed 6291475]
111. Engelhard D, Stutman HR, Marks MI. Interaction of ketoconazole with rifampin and isoniazid. N Engl J Med. 1984; 311:1681-3. [IDIS 194105] [PubMed 6095080]
112. Stevens DA. Ketoconazole metamorphosis: an antimicrobial becomes an endocrine drug. Arch Intern Med. 1985; 145:813-5. [PubMed 3994459]
113. Sheperd FA, Hoffert B, Evans WK et al. Ketoconazole: use in the treatment of ectopic adrenocorticotropic hormone production and Cushing’s syndrome in small-cell lung cancer. Arch Intern Med. 1985; 145:863-4. [IDIS 199179] [PubMed 2986567]
114. Angeli A, Frairia R. Ketoconazole therapy in Cushing’s disease. Lancet. 1985; 1:821. [IDIS 198857] [PubMed 2858699]
115. Carvalho D, Pignatelli D, Resende C. Ketoconazole for hirsutism. Lancet. 1985; 2:560. [IDIS 204625] [PubMed 2863584]
116. Holland FJ, Fishman L, Bailey JD et al. Ketoconazole in the management of precocious puberty not responsive to LHRH-analogue therapy. N Engl J Med. 1985; 312:1023-8. [IDIS 198728] [PubMed 2984563]
117. Pont A, Goldman ES, Sugar AM et al. Ketoconazole-induced increase in estradiol-testosterone ratio: probable explanation for gynecomastia. Arch Intern Med. 1985; 145:1429-31. [IDIS 202894] [PubMed 4040740]
118. Pottage JC, Kessler HA, Goodrich JM et al. In vitro activity of ketoconazole against herpes simplex virus. Antimicrob Agents Chemother. 1986; 30:215-9. [IDIS 220405] [PubMed 3021048]
119. Minagawa H, Kitaura K, Nakamizo N. Effects of pH on the activity of ketoconazole against Candida albicans. Antimicrob Agents Chemother. 1983; 23:105-7. [IDIS 164455] [PubMed 6299178]
120. Shadomy S, Espinel-Ingroff A, Kerkering TM. In-vitro studies with four new antifungal agents: BAY n7133, bifonazole (BAY h 4502), ICI 153,066 and Ro 14-4767/002. Sabouraudia. 1984; 22:7-15. [PubMed 6322364]
121. Lefler E, Stevens DA. Inhibition and killing of Candida albicans in vitro by five imidazoles in clinical use. Antimicrob Agents Chemother. 1984; 25:450-4. [IDIS 184277] [PubMed 6375555]
122. Espinel-Ingroff A, Shadomy S, Gebhart RJ. In vitro studies with R 51,211 (itraconazole). Antimicrob Agents Chemother. 1984; 26:5-9. [IDIS 187623] [PubMed 6089654]
123. Bergan T, Vangdal M. In vitro activity of antifungal agents against yeast species. Chemotherapy. 1983; 29:104-10. [IDIS 169053] [PubMed 6301773]
124. Gebhart RJ, Espinel-Ingroff A, Shadomy S. In vitro susceptibility studies with oxiconazole (Ro 13-8996). Chemotherapy. 1984; 30:244-7. [IDIS 187989] [PubMed 6086246]
125. Tavitian A, Raufman JP, Rosenthal LE et al. Ketoconazole-resistant Candida esophagitis in patients with acquired immunodeficiency syndrome. Gastroenterology. 1986; 90:443-5. [IDIS 210426] [PubMed 3510145]
126. Ryley JF, Wilson RG, Barrett-Bee KJ. Azole resistance in Candida albicans. Sabouraudia. 1984; 22:53-63. [PubMed 6322363]
127. Thomas AH. Suggested mechanisms for the antimycotic activity of the polyene antibiotics and the N-substituted imidazoles. J Antimicrob Chemother. 1986; 17:269-79. [PubMed 3516967]
128. Sud IJ, Feingold DS. Mechanisms of action of the antimycotic imidazoles. J Invest Dermatol. 1981; 76:438-41. [IDIS 133194] [PubMed 7017013]
129. Pye GW, Marriott MS. Inhibition of sterol C14 demethylation by imidazole-containing antifungals. Sabouraudia. 1982; 20:325-9. [PubMed 6760419]
130. Beggs WH, Andrews FA, Sarosi GA. Minireview: action of imidazole-containing antifungal drugs. Life Sci. 1981; 28:111-8. [PubMed 7019609]
131. Beggs WH. Growth phase in relation to ketoconazole and miconazole susceptibilities of Candida albicans. Antimicrob Agents Chemother. 1984; 25:316-8. [PubMed 6326664]
132. Beggs WH. Influence of growth phase on the susceptibility of Candida albicans to butoconazole, oxiconazole, and sulconazole. J Antimicrob Chemother. 1985; 16:397-9. [PubMed 3902762]
133. Van den Bossche H, Ruysschaert JM, Defrise-Quertain F et al. The interaction of miconazole and ketoconazole with lipids. Biochem Pharmacol. 1982; 31:2609-17. [PubMed 6291539]
134. Samples JR, Binder PS, Luibel FJ et al. Acanthamoeba keratitis possibly acquired from a hot tub. Arch Ophthalmol. 1984; 102:707-10. [PubMed 6372764]
135. Scully RE, Mark EJ, McNeely BU et al. Case records of the Massachusetts General Hospital: case 10-1985. N Engl J Med. 1985; 312:634-41. [PubMed 3883164]
136. Theodore FH, Jakobiec FA, Juechter KB et al. The diagnostic value of a ring infiltrate in Acanthamoebic keratitis. Ophthalmology. 1985; 92:1471-9. [PubMed 4080321]
137. Hirst LW, Green WR, Merz W et al. Management of Acanthamoeba keratitis: a case report and review of the literature. Ophthalmology. 1984; 91:1105-11. [PubMed 6093021]
138. Anon. Acanthamoeba keratitis associated with contact lenses—United States. MMWR Morb Mortal Wkly Rep. 1986; 35:405-8. [PubMed 3088418]
139. Cohen EJ, Buchanan HW, Laughrea PA et al. Diagnosis and management of Acanthamoeba keratitis. Am J Ophthalmol. 1985; 100:389-95. [IDIS 206426] [PubMed 4037025]
140. Moore MB, McCulley JP, Luckenbach M et al. Acanthamoeba keratitis associated with soft contact lenses. Am J Ophthalmol. 1985; 100:396-403. [IDIS 206427] [PubMed 3898851]
141. Doble N, Hykin P, Shaw R et al. Pulmonary Mycobacterium tuberculosis in acquired immune deficiency syndrome. BMJ. 1985; 291:849-50. [IDIS 205189] [PubMed 3931740]
142. Ferguson RM, Sutherland DER, Simmons RL et al. Ketoconazole, cyclosporin metabolism, and renal transplantation. Lancet. 1982; 2:882-3. [IDIS 158221] [PubMed 6126744]
143. Dieperink H, Moller J. Ketoconazole and cyclosporin. Lancet. 1982; 2:1217. [IDIS 161092] [PubMed 6128518]
144. Shepard JH, Canafax DM, Simmons RL et al. Cyclosporine-ketoconazole: a potentially dangerous drug-drug interaction. Clin Pharm. 1986; 5:468. [IDIS 216399] [PubMed 3720214]
145. Daneshmend TK. Ketoconazole-cyclosporin interaction. Lancet. 1982; 2:1342-3. [IDIS 161858] [PubMed 6128627]
146. Hansten PD, Horn JR. Ketoconazole (Nizoral) interactions. Drug Interact Newsl. 1986; 6(Updates):U19-20.
147. Murphy E, Hannon D, Callaghan B. Ketoconazole-theophylline interaction. Ir Med J. 1987; 80:123-4. [PubMed 3597030]
148. National Committe for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M27-A. Wayne, PA: NCCLS; 1997 Jun.
149. Huang YC, Colaizzi JL, Bierman RH et al. Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrob Agents Chemother. 1986; 30:206-10. [IDIS 220403] [PubMed 3767339]
150. Brown MW, Maldonado AL, Meredith CG et al. Effect of ketoconazole on hepatic oxidative drug metabolism. Clin Pharmacol Ther. 1985; 37:290-7. [IDIS 197455] [PubMed 3971653]
151. Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med. 1987; 317:812-8. [IDIS 233977] [PubMed 3306384]
152. Litt MR, Bell WR, Lepor HA. Disseminated intravascular coagulation in prostatic carcinoma reversed by ketoconazole. JAMA. 1987; 258:1361-2. [IDIS 233299] [PubMed 3625935]
153. Umstead GS, Babiak LM, Tejwani S. Immune hemolytic anemia associated with ketoconazole therapy. Clin Pharm. 1987; 6:499-500. [IDIS 230326] [PubMed 3690997]
154. Loli P, Berselli ME, Tagliaferri M. Use of ketoconazole in the treatment of Cushing’s syndrome. J Clin Endocrinol Metab. 1986; 63:1365-71. [IDIS 225322] [PubMed 3023421]
155. Lamberts SWJ, Bons EG, Bruining HA et al. Differential effects of the imidazole derivatives etomidate, ketoconazole and miconazole and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical cells. J Pharmacol Exp Ther. 1987; 240:259-64. [PubMed 3027305]
156. Pont A, Williams PL, Loose DS et al. Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med. 1982; 97:370-2. [IDIS 156077] [PubMed 6287893]
157. Tucker WS Jr, Snell BB, Island DP et al. Reversible adrenal insufficiency induced by ketoconazole. JAMA. 1985; 253:2413-4. [IDIS 198754] [PubMed 3981770]
158. Howden CW. Effect of ketoconazole on the synthesis of cortisol. J Infect Dis. 1986; 153:378. [IDIS 211056] [PubMed 3944491]
159. Best TR, Jenkins JK, Murphy FY et al. Persistent adrenal insufficiency secondary to low-dose ketoconazole therapy. Am J Med. 1987; 82:676-80. [IDIS 228333] [PubMed 3826130]
160. White MC, Kendall-Taylor P. Adrenal hypofunction in patients taking ketoconazole. Lancet. 1985; 1:44-5. [PubMed 2856964]
161. Pillans PI, Cowan P, Whitelaw D. Hyponatraemia and confusion in a patient taking ketoconazole. Lancet. 1985; 1:821-2. [IDIS 198858] [PubMed 2858700]
162. Clissold SP. Pharmacokinetic properties. In: Jones HE, ed. Ketoconazole today: a review of clinical experience. Manchester, England: ADIS Press Ltd; 1987:19-28.
163. Ginsburg CM, McCracken GH Jr, Olsen K. Pharmacology of ketoconazole suspension in infants and children. Antimicrob Agents Chemother. 1983; 23:787-19. [IDIS 170772] [PubMed 6307138]
164. Lake-Bakaar G, Scheuer PJ, Sherlock S. Hepatic reactions associated with ketoconazole in the United Kingdom. BMJ. 1987; 294:419-22. [IDIS 226772] [PubMed 3101906]
165. Tabor E. Hepatotoxicity of ketoconazole in men and in patients under 50. N Engl J Med. 1987; 316:1606. [IDIS 230809] [PubMed 3587297]
166. McCance DR, Ritchie CM, Sheridan B et al. Acute hypoadrenalism after treatment with ketoconazole. Lancet. 1987; 1:573. [IDIS 226810] [PubMed 2881126]
167. Lewis JH, Zimmerman HJ, Benson GD et al. Hepatic injury associated with ketoconazole therapy. Gastroenterology. 1984; 86:503-13. [IDIS 181840] [PubMed 6319220]
168. Duarte PA, Chow CC, Simmons F et al. Fatal hepatitis associated with ketoconazole therapy. Arch Intern Med. 1984; 144:1069-70. [IDIS 184764] [PubMed 6324708]
169. Bercoff E, Bernuau J, Degott C et al. Ketoconazole-induced fulminant hepatitis. Gut. 1985; 26:636-8. [IDIS 203609] [PubMed 4007605]
170. Dismukes WE, Stamm AM, Graybill JR et al. Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. Ann Intern Med. 1983; 98:13-20. [IDIS 162785] [PubMed 6293361]
171. Kowal J. The effect of ketoconazole on steroidogenesis in cultured mouse adrenal cortex tumor cells. Endocrinology. 1983; 112:1541-3. [PubMed 6299699]
172. Loose DS, Kan PB, Hirst MA et al. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest. 1983; 71:1495-9. [PubMed 6304148]
173. Engelhardt D, Dorr G, Jaspers C et al. Ketoconazole blocks cortisol secretion in man by inhibition of adrenal 11β-hydroxylase. Klin Wochenschr. 1985; 63:607-12. [PubMed 2993735]
174. Santen RJ, Van den Bossche H, Symoens J et al. Site of action of low dose ketoconazole on androgen biosynthesis in men. J Clin Endocrinol Metab. 1983; 57:732-6. [IDIS 176459] [PubMed 6309882]
175. Kan PB, Hirst MA, Feldman D. Inhibition of steroidogenic cytochrome P-450 enzymes in rat testis by ketoconazole and related imidazole anti-fungal drugs. J Steroid Biochem. 1985; 23:1023-9. [PubMed 3841572]
176. Nagai K, Miyamori I, Ikeda M et al. Effect of ketoconazole (an imidazole antimycotic agent) and other inhibitors of steroidogenesis on cytochrome P450-catalyzed reactions. J Steroid Biochem. 1986; 24:321-3. [PubMed 3702414]
177. Baxter JG, Brass C, Schentag JJ et al. Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs. J Pharm Sci. 1986; 75:443-7. [IDIS 216962] [PubMed 3735080]
178. Lowe FC, Somers WJ. The use of ketoconazole in the emergency management disseminated intravascular coagulation due to metastatic prostatic cancer. J Urol. 1987; 137:1000-2. [IDIS 229184] [PubMed 3573156]
179. Nicolle P, Pontin A, Sarembock L. High-dose ketoconazole therapy in prostatic cancer: a pilot study. S Afr Med J. 1985; 67:888-9. [IDIS 205320] [PubMed 4002070]
180. Trachtenberg J. Ketoconazole therapy in advanced prostatic cancer. J Urol. 1984; 132:61-3. [IDIS 187226] [PubMed 6328052]
181. Williams G, Kerle DJ, Ware H et al. Objective responses to ketoconazole therapy in patients with relapsed progressive prostatic cancer. Br J Urol. 1986; 58:45-51. [PubMed 3947856]
182. Vanuytsel L, Ang KK, Vantongelen K et al. Ketoconazole therapy for advanced prostatic cancer: feasibility and treatment results. J Urol. 1987; 137:905-8. [IDIS 229179] [PubMed 2952808]
183. Pont A. Long-term experience with high dose ketoconazole therapy in patients with stage D2 prostatic carcinoma. J Urol. 1987; 137:902-4. [IDIS 229178] [PubMed 2437334]
184. Trachtenberg J. Ketoconazole therapy in advanced prostatic cancer. J Urol. 1987; 137:959. [IDIS 229182] [PubMed 3573195]
185. Holland FJ, Kirsch SE, Selby R. Gonadotropin-independent precocious puberty (“testotoxicosis:): influence of maturational status on response to ketoconazole. J Clin Endocrinol Metab. 1987; 64:328-33. [IDIS 225669] [PubMed 3539979]
186. Root AW, Zamanillo J, Duckett G et al. Gondadotropin-independent isosexual precocity in a boy with tuberous sclerosis: effect of ketoconazole. J Pediatr. 1986; 109:1012-5. [IDIS 224967] [PubMed 3097292]
187. Singhal T, Bajpai A, Kalra V et al. Successful treatment of Acanthamoeba meningitis with combination oral antimicrobials. Ped Infect Dis J. 2001; 20:623-7.
188. Svejgaard E, Ranek L. Hepatic dysfunction and ketoconazole therapy. Ann Intern Med. 1982; 96(6 Part 1):788-9. [IDIS 152654] [PubMed 6283980]
189. Tkach JR, Rinaldi MG. Severe hepatitis associated with ketoconazole therapy for chronic mucocutaneous candidiasis. Cutis. 1982; 29:482-3. [PubMed 6284445]
190. Rollman O, Lööf L. Hepatic toxicity of ketoconazole. Br J Dermatol. 1983; 108:376-8. [IDIS 168054] [PubMed 6299322]
191. Janssen PAJ, Symoens JE. Hepatic reactions during ketoconazole treatment. Am J Med. 1983; 74(Suppl):80-5. [IDIS 165060] [PubMed 6129799]
192. Pitrak DL, Andersen BR. Cerebral blastomycoma after ketoconazole therapy for respiratory tract blastomycosis. Am J Med. 1989; 86:713-4. [IDIS 255557] [PubMed 2729325]
193. Boughton K. Ketoconazole and hepatic reactions. S Afr Med J. 1983; 63:955. [IDIS 174106] [PubMed 6304923]
194. Meurice JC, Lecomte P, Renard JP et al. Interaction miconazole et sulfamides hypoglycémiants. Presse Med. 1983; 18:1670.
195. Astohova AV. Miconazole. In: Dukes MNG, ed. Side effects of drugs. Annual 8. New York: Elsevier Science Publishing Co, Inc; 1984:270.
196. Marcon MJ, Durrell DE, Powell DA et al. In vitro activity of systemic antifungal agents against Malassezia furfur. Antimicrob Agents Chemother. 1987; 31:951-3. [IDIS 232046] [PubMed 3619430]
197. Loupi E, Descotes J, Lery N et al. Interactions médicamenteuses et miconazole: a propos de 10 observations. Thérapie. 1982; 37:437-41.
198. Lake-Bakaar G, Tom W, Lake-Bakaar D et al. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1988; 109:471-3. [IDIS 245862] [PubMed 3415107]
199. Lelawongs P, Barone JA, Colaizzi JL et al. Effect of food and gastric acidity on absorption of orally administered ketoconazole. Clin Pharm. 1988; 7:228-35. [IDIS 239224] [PubMed 3356120]
200. Panel on Antiretroviral Guidelines for Adults and Adolescents, US Department of Health and Human Services (HHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (February 12, 2013). Updates may be available at HHS AIDS Information (AIDSinfo) website.
201. Aabo K, De Coster R. Hypertension during high-dose ketoconazole treatment: a probable mineralocorticosteroid effect. Lancet. 1987; 2:637-8. [IDIS 233788] [PubMed 2887934]
202. Pfaller A, Rex JH, Rinaldi MG. Antifungal susceptibility testing: technical advances and potential clinical applications. Clin Infect Dis. 1997; 24:776-84. [IDIS 386039] [PubMed 9142769]
203. Bristol-Myers Squibb. Reyataz (atazanavir sulfate) capsules prescribing information. Princeton, NJ; 2013 Aug.
204. Janssen Pharmaceuticals. Prezista (darunavir) oral suspension and tablets prescribing information. Titusville, NJ; 2013 Apr.
205. ViiV Healthcare. Lexiva (fosamprenavir calcium) tablets and oral suspension prescribing information. Research Triangle Park, NC; Apr 2013.
206. Merck Sharp & Dohme Corp. Crixivan (indinavir sulfate) capsules prescribing information. Whitehouse Station, NJ; 2012 Apr.
207. AbbVie Inc. Kaletra (lopinavir/ritonavir) tablets and oral solution prescribing information. North Chicago, IL; 2013 Jul.
208. ViiV Healthcare. Viracept (nelfinavir mesylate) tablets and oral powder prescribing information. Research Triangle Park, NC; 2013 May.
210. Genentech USA Inc. Invirase (saquinavir mesylate) capsules and tablets prescribing information. South San Francisco, CA; 2012 Nov.
211. Boehringer Ingelheim Pharmaceutics Inc. Aptivus (tipranavir) capsules and oral solution prescribing information. Ridgefield, CT; 2012 Apr.
212. ViiV Healthcare. Rescriptor (delavirdine mesylate) tablets prescribing information. Research Triangle Park, NC; 2012 Apr.
213. Bristol-Myers Squibb. Sustiva (efavirenz) capsules and tablets prescribing information. Princeton, NJ; 2013 May.
214. Janssen. Intelence (etravirine) tablets prescribing information.Titusville, NJ; 2013 Feb.
216. Greene NB, Baughman RP, Kim CK et al. Failure of ketoconazole in an immunosuppressed patient with pulmonary blastomycosis. Chest. 1985; 88:640-1. [IDIS 207498] [PubMed 3899536]
217. Thiele JS, Buechner HA, Cook EW Jr. Failure of ketoconazole in two patients with blastomycosis. Chest. 1985; 88:640-1. [IDIS 207498] [PubMed 3899536]
218. McManus EJ, Jones JM. The use of ketoconazole in the treatment of blastomycosis. Am Rev Respir Dis. 1986; 133:141-3. [IDIS 211606] [PubMed 3942371]
219. Sugar AM. Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob Agents Chemother. 1995; 39:1907-12.
220. Bradsher RW, Rice DC, Abernathy RS. Ketoconazole therapy for endemic blastomycosis. Ann Intern Med. 1983; 103(6 Part 1):872-9.
221. Abadie-Kemmerly S, Pankey GA, Dalovisio JR. Failure of ketoconazole treatment of Blastomyces dermatitidis due to interaction of isoniazid and rifampin. Ann Intern Med. 1988; 109:844-5. [IDIS 248041] [PubMed 3190036]
222. Holmes B, Brogden RN, Richards DM. Norfloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1985; 30:482-513. [IDIS 209686] [PubMed 3908074]
223. Overbeek BP, Rozenberg-Arska M, Verhoef J. Do quinolones really augment the antifungal effect of amphotericin B in vitro? Drugs Exp Clin Res. 1985; 11:745-6.
224. Farwell AP, Devlin JT, Stewart JA. Total suppression of cortisol excretion by ketoconazole in the therapy of the ectopic adrenocorticotropic hormone syndrome. Am J Med. 1988; 84:1063-6. [IDIS 242041] [PubMed 3376976]
225. Yeung EY, Huang SC, Tsai RJ. Acanthamoeba keratitis presenting as dendritic keratitis in a soft contact lens wearer. Chang Gung Med J. 2002; 25:201-6. [PubMed 12022742]
226. Tibotec Therapeutics. Edurant (rilpivirine) tablets prescribing information. Raritan, NJ; 2012 Aug.
227. Glynn AM, Slaughter RL, Brass C et al. Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion. Clin Pharmacol Ther. 1986; 39:654-9. [IDIS 217705] [PubMed 3709030]
228. Kandrotas RJ, Slaughter RL, Corstiaan B et al. Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol. Clin Pharmacol Ther. 1987; 42:465-70. [IDIS 234787] [PubMed 3311551]
229. Khosla S, Wolfson JS, Demerjian Z et al. Adrenal crisis in the setting of high-dose ketoconazole therapy. Arch Int Med. 1989; 149:802-4.
230. Britton H, Shehab Z, Lightner E et al. Adrenal response in children receiving high doses of ketoconazole for systemic coccidioidomycosis. J Pediatr. 1988; 112:488-92. [IDIS 239538] [PubMed 2831330]
232. Zurcher RM, Frey BM, Frey FJ. Impact of ketoconazole on the metabolism of prednisolone. Clin Pharmacol Ther. 1989; 45:366-72. [IDIS 253522] [PubMed 2639662]
233. Corticosteroids/ketoconazole. In: Tatro DS, Olin BR, eds. Drug interaction facts. St. Louis; JB Lippincott Co; 1990 (October):220.
234. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Treatment of blastomycosis and histoplasmosis with ketoconazole: results of a prospective randomized clinical trial. Ann Intern Med. 1985; 103:(6 Part 1):861-72.
235. Saag MS, Dismukes WE. Treatment of histoplasmosis and blastomycosis. Chest. 1988; 93:848-51. [IDIS 311626] [PubMed 3280262]
236. Bradsher RW. Blastomycosis: fungal infections of the lung update: 1989. Semin Respir Infect. 1990; 5:105-10. [PubMed 2247705]
237. Davies SF, Sarosi GA. Blastomycosis. Eur J Clin Microbiol Infect Dis. 1989; 8:474-9. [PubMed 2502412]
239. Murphy PA. Blastomycosis. JAMA. 1989; 261:3159-62. [IDIS 254594] [PubMed 2716144]
240. Salem HT, Salah M, Farid A et al. Oral versus local treatment of vaginal candidosis. Int J Gynaecol Obstet. 1989; 30:57-62. [PubMed 2572475]
241. van der Meijden WI, van der Hoek JC, Staal HJ et al. Double-blind comparison of 200-mg ketoconazole oral tablets and 1200-mg miconazole vaginal capsule in the treatment of vaginal candidosis. Eur J Obstet Gynecol Reprod Biol. 1986; 22:133-8. [PubMed 3525273]
242. Puolakka J, Tuimala R. Comparison between oral ketoconazole and topical miconazole in the treatment of vaginal candidiasis. Acta Obstet Gynecol Scand. 1983; 62:575-7. [PubMed 6322505]
243. Miller PI, Humphries M, Grassick K. A single-blind comparison of oral and intravaginal treatments in acute and recurrent vaginal candidosis in general practice. Pharmatherapeutica. 1984; 3:582-7. [PubMed 6328542]
244. Bingham JS. Single blind comparison of ketoconazole 200 mg oral tablets and clotrimazole 100 mg vaginal tablets and 1% cream in treating acute vaginal candidosis. Br J Vener Dis. 1984; 60:175-7. [PubMed 6329405]
245. Benhamou E, Hartmann O, Nogues C et al. Does ketoconazole prevent fungal infection in children treated with high dose chemotherapy and bone marrow transplantation? Results of a randomized placebo-controlled trial. Bone Marrow Transplant. 1991; 7:127-31. [PubMed 2049556]
246. Shepp DH, Klosterman A, Siegel MS et al. Comparative trial of ketoconazole and nystatin for prevention of fungal infection in neutropenic patients treated in a protective environment. J Infect Dis. 1985; 152:1257-63. [IDIS 209089] [PubMed 3905986]
247. Turhan A, Connors JM, Klimo P. Ketoconazole versus nystatin as prophylaxis against fungal infection for lymphoma patients receiving chemotherapy. Am J Clin Oncol. 1987; 10:355-9. [PubMed 2441593]
248. Vogler WR, Malcom LG, Winton EF. A randomized trial comparing ketoconazole and nystatin prophylactic therapy in neutropenic patients. Cancer Invest. 1987; 5:267-73. [PubMed 3664330]
249. Walsh TJ, Rubin M, Hathorn J et al. Amphotericin B vs high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients: a prospective, randomized study. Arch Intern Med. 1991; 151:765-70. [IDIS 280492] [PubMed 2012462]
250. Saenz RE, Paz H, Berman JD. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am J Med. 1990; 89:147-55. [IDIS 270063] [PubMed 2166429]
251. Piscitelli SC, Goss TF, Wilton JH et al. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother. 1991; 35:1765-71. [IDIS 287975] [PubMed 1952845]
263. Janssen Pharmaceuticals, Inc. Nizoral (ketoconazole) tablets prescribing information. Titusville, NJ; 2013 Jul.
267. Magnasco AJ, Magnasco LD. Interaction of ketoconazole and ethanol. Clin Pharm. 1986; 5:522-3. [IDIS 216409] [PubMed 2941211]
268. Meyboom RH, Pater BW. [Hypersensitivity to alcoholic beverages during treatment with ketoconazole]. Ned Tijdschr Geneeskd. 1989; 133:1463-4. [PubMed 2797244]
269. Mead Johnson Oncology Products. Taxol (paclitaxel) injection prescribing information. Princeton, NJ; 2000 Jul.
271. Sobel JD. Recurrent vulvovaginal candidiasis: a prospective study of the efficacy of maintenance ketoconazole therapy. N Engl J Med. 1986; 315:1455-8. [IDIS 223207] [PubMed 3537785]
273. Chin TWF, Loeb M, Fong IW. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob Agents Chemother. 1995; 39:1671-5. [IDIS 352188] [PubMed 7486898]
274. Sharma JB, Buckshee K, Gulati N. Oral ketoconazole and miconazole vaginal pessary treatment for vaginal candidosis. Aust N Z J Obstet Gynaecol. 1991; 31:276-8. [PubMed 1804095]
275. Gold WL, Vellend H, Salit IE et al. Successful treatment of systemic and local infections due to Exophiala species. Clin Infect Dis. 1994; 19:339-41. [IDIS 334166] [PubMed 7986913]
276. Klausner MA. Dear Pharmacist letter. Titusville, NJ: Janssen Pharmaceutica; 1995.
277. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994; 56:601-7. [IDIS 342218] [PubMed 7995001]
278. Greenblatt DJ, von Moltke LL, Harmatz JS et al. Interaction of triazolam and ketoconazole. Lancet. 1995; 345: Letter. [IDIS 341080] [PubMed 7823684]
280. Smith GH. Treatment of infections in the patient with acquired immunodeficiency syndrome. Arch Intern Med. 1994; 154:949-73. [IDIS 329350] [PubMed 8179453]
281. American Thoracic Society. Fungal infection in HIV-infected persons. Am J Respir Crit Care Med. 1995; 152:816-22. [IDIS 352046] [PubMed 7633749]
283. Moran GP, Sullivan DJ, Henman MC et al. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob Agents Chemother. 1997; 41:617-23. [IDIS 383166] [PubMed 9056003]
284. Cersosimo RJ, Carr D. Prostate cancer: current and evolving strategies. Am J Health Syst Pharm. 1996; 53:381-96. [IDIS 360612] [PubMed 8673658]
285. Small EJ, Baron AD, Fippin L et al. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol. 1997; 157:1204-7. [IDIS 383657] [PubMed 9120902]
286. Prostatic cancer. From: PDQ Information for Health Care Professionals (database). Bethesda, MD: National Cancer Institute; 1997 Dec.
288. Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone Inc; 1995:2300-9,2316-23,2336-8,2350-1,2371,2388-9,2413,2428-36,2714-9.
289. Favel A, Michel-Nguyen A, Chastin C et al. In-vitro susceptibility pattern of Candida lusitaniae and evaluation of the Etest method. J Antimicrob Chemother. 1997; 39:591-6. [IDIS 387158] [PubMed 9184357]
290. Kauffman CA. Role of azoles in antifungal therapy. Clin Infect Dis. 1996; 22(Suppl 2:S148-53. [IDIS 367021] [PubMed 8722843]
291. Reynolds JEF, ed. Martindale: the extra pharmacopoeia. 31st ed. London: The Pharmaceutical Press; 1996:383-402.
292. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med. 1994; 220:263-72.
293. Klein NC, Cunha BA. New antifungal drugs for pulmonary mycoses. Chest. 1996; 110:525-32. [IDIS 371846] [PubMed 8697859]
294. Armstrong D. Treatment of opportunistic fungal infections. Clin Infect Dis. 1993; 16:1-9. [IDIS 307821] [PubMed 8448281]
295. Yancey RW, Perlino CA, Kaufman L. Asymptomatic blastomycosis of the central nervous system with progression in patients given ketoconazole therapy: a report of two cases. J Infect Dis. 1991; 164:807-10. [IDIS 289561] [PubMed 1894941]
296. Pappas PG, Pottage JC, Powderly WG et al. Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1992; 116:847-53. [IDIS 296295] [PubMed 1567099]
297. Mangino JE, Pappas PG. Itraconazole for the treatment of histoplasmosis and blastomycosis. Int J Antimicrob Agents. 1995; 5:219-25. [PubMed 18611672]
298. Chao D, Steier KJ, Gomila R. Update and review of blastomycosis. J Am Osteopath Assoc. 1997; 97:525-32. [PubMed 9313349]
299. Bradsher RW. Therapy of blastomycosis. Semin Respir Infect. 1997; 12:263-7. [PubMed 9313298]
300. Varkey B. Blastomycosis in children. Semin Respir Infect. 1997; 12:235-42. [PubMed 9313295]
301. Chapman SW, Lin AC, Hendricks KA et al. Endemic blastomycosis in Mississippi: epidemiological and clinical studies. Semin Respir Infect. 1997; 12:219-28. [PubMed 9313293]
302. Pappagianis D. Coccidioidomycosis. Semin Dermatol. 1993; 12:301-9. [PubMed 8312146]
303. Galgiani JN, Ampel NM. Coccidioidomycosis in human immunodeficiency virus—infected patients. J Infect Dis. 1990; 162:1165-9. [IDIS 274447] [PubMed 2230241]
304. Ross JB, Levine B, Catanzaro A et al. Ketoconazole for treatment of chronic pulmonary coccidioidomycosis. Ann Intern Med. 1982; 96:440-3. [IDIS 147424] [PubMed 6279005]
305. Catanzaro A, Einstein H, Levine B et al. Ketoconazole for treatment of disseminated coccidioidomycosis. Ann Intern Med. 1982; 96:436-40. [IDIS 147423] [PubMed 6279004]
306. Perfect JR, Durack DT, Hamilton JD et al. Failure of ketoconazole in cryptococcal meningitis. JAMA. 1982; 247:3349-51. [IDIS 151469] [PubMed 6283185]
310. Goldani LZ, Sugar A. Paracoccidioidomycosis and AIDS: an overview. Clin Infect Dis. 1995; 21:1275-81. [IDIS 356544] [PubMed 8589154]
311. Nishioka S. Paracoccidioidomycosis and AIDS. Clin Infect Dis. 1996; 22:1132. [IDIS 368827] [PubMed 8783743]
312. Kauffman CA. Old and new therapies for sporotrichosis. Clin Infect Dis. 1995; 21:981-5. [IDIS 355567] [PubMed 8645851]
313. Dall L, Salzman G. Treatment of pulmonary sporotrichosis with ketoconazole. Rev Infect Dis. 1987; 9:795-8. [IDIS 232257] [PubMed 3326126]
315. Wali JP, Aggarwal P, Gupta U et al. Ketoconazole in the treatment of antimony- a pentamidine-resistant Kala-Azar. J Infect Dis. 1992; 166:215-6. [IDIS 298740] [PubMed 1607703]
316. Navin TR, Arana MA, Arana FE et al. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous Leishmaniasis in Guatemala. J Infect Dis. 1992; 165:528-34. [IDIS 292342] [PubMed 1311351]
317. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic development in the last 10 years. Clin Infect Dis. 1997; 24:684-703. [IDIS 384365] [PubMed 9145744]
318. Halim MA, Alfurayh O, Kalin ME et al. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in a renal transplant recipient after the occurrence of pancreatitis due to stibogluconate. Clin Infect Dis. 1993; 16:397-9. [IDIS 310978] [PubMed 8135901]
319. Despommier DD, Gwadz RW, Hotez PJ. Parasitic Diseases. 3rd ed. New York: Springer-Verlag; 1995:203-9.
320. Hay KD. Candidosis of the oral cavity: recognition and management. Drugs. 1988; 36:633-42. [IDIS 249264] [PubMed 3063501]
322. Weinert M, Grimes RM, Lynch DP. Oral manifestations of HIV infection. Ann Intern Med. 1996; 125:485-96. [PubMed 8779462]
323. Drake LA, Dinehart SM, Farmer ER et al et al. Guidelines of care for superficial mycotic infections of the skin: mucocutaneous candidiasis. J Am Acad Dermatol. 1996; 34:110-5. [IDIS 361417] [PubMed 8543679]
324. Drake LA, Dinehart SM, Farmer ER et al. Guidelines of care for superficial mycotic infections of the skin: pityriasis (tinea) versicolor. J Am Acad Dermatol. 1996; 34:287-9. [IDIS 363963] [PubMed 8642095]
325. Drake LA, Dinehart SM, Farmer ER et al. Guidelines of care for superficial mycotic infections of the skin: tinea capitis and tinea barbae. J Am Acad Dermatol. 1996; 23:290- 4.
328. Rowe JM, Ciobanu N, Ascensao J et al et al. Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation: a report from the Eastern Cooperative Oncology Group (ECOG). Ann Intern Med. 1994; 120:143-58. [IDIS 323859] [PubMed 8256974]
332. Pappas PG. Blastomycosis in the immunocompromised patient. Semin Respir Infect. 1997; 12:243-51. [PubMed 9313296]
333. Davies SF, Sarosi GA. Epidemiological and clinical features of pulmonary blastomycosis. Semin Respir Infect. 1997; 12:206-18. [PubMed 9313292]
334. Herrod HG. Chronic mucocutaneous candidiasis in childhood and complications of non-Candidal infection: a report of the Pediatric Immunodeficiency Collaborative Study Group. J Pediatr. 1990; 116:377-82. [PubMed 2308026]
335. Restrepo A. Treatment of tropical mycoses. J Am Acad Dermatol. 1994; 31:S91-102. [IDIS 335778] [PubMed 8077517]
336. Pepose JS, Holland G, Wilhelmus KR. Ocular infections & immunology. St. Louis, MO:Mosby—Year Book Inc; 1996:1048-61,1262-85.
337. Alexander BD, Perfect JR. Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches. Drugs. 1997; 54:657-78. [PubMed 9360056]
338. Klausner MA. Dear doctor letter regarding important drug warning of Hismanal (astemizole). Titusville, NJ: Janssen Pharmaceutica; 1998 Feb.
339. Doering PL, Santiago TM. Drugs for the treatment of vulvovaginal candidiasis: comparative efficacy of agents and regimens. DICP. 1990; 24:1078-83. [IDIS 274670] [PubMed 2275233]
340. Sobel JD. Vaginitis. N Engl J Med. 1997; 337:1896-903. [IDIS 401347] [PubMed 9407158]
342. Berwaerts JJ, Verhelst JA, Verhaert GC et al. Corticotropin-dependent Cushing’s syndrome in older people: presentation of five cases and therapeutical use of ketoconazole. J Am Geriatr Soc. 1998; 46:880-4. [IDIS 411296] [PubMed 9670876]
343. Sobel JD, Faro S, Force RW et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998; 178:203-11. [IDIS 402301] [PubMed 9500475]
344. Tobin MJ. Vulvovaginal candidiasis: topical vs. oral therapy. Am Fam Physician. 1995; 51:1715-24. [IDIS 348350] [PubMed 7754931]
345. Krieger JN. New sexually transmitted diseases treatment guidelines. J Urol. 1995; 154: 209-13.
346. Sobel JD. Controversial aspects in the management of vulvovaginal candidiasis. J Am Acad Dermatol. 1994; 31: S10-3. [IDIS 335764] [PubMed 8077494]
347. Sobel JD. Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis. 1992; 14(Suppl 1):S148-53.
348. Spinillo A, Capuzzo E, Gulminetti R et al. Prevalence of and risk factors for fungal vaginitis caused by non-albicans species. Am J Obstet Gynecol. 1997; 176: 138-41. [PubMed 9024104]
349. Chaim W. Fungal vaginitis caused by nonalbicans species. Am J Obstet Gynecol. 1997; 177: 485. [IDIS 393344] [PubMed 9290485]
350. Spinillo A, Capuzzo E. Fungal vaginitis caused by nonalbicans species. Am J Obstet Gynecol. 1997; 177: 485-6.
351. Redondo-Lopez V, Lynch M, Schmitt C et al. Torulopsis glabrata vaginitis: clinical aspects and susceptibility to antifungal agents. Obstet Gynecol. 1990; 76: 651-5.
352. Gupta AK, Einarson TR, Summerbell RC et al. An overview of topical antifungal therapy in dermatomycoses: a North American perspective. Drugs. 1998; 55:645-74. [PubMed 9585862]
353. Piérard GE, Arrese JE, Piérard-Franchimont C. Treatment and prophylaxis of tinea infections. Drugs. 1996; 52:209-24. [PubMed 8841739]
354. Sunenshine PJ, Schwartz RA, Janniger CK. Tinea versicolor: an update. Cutis. 1998; 61:65-72. [PubMed 9515210]
355. Assaf RR, Weil ML. The superficial mycoses. Dermatol Clin. 1996; 14:57-67. [PubMed 8821158]
356. Lesher JL. Recent developments in antifungal therapy. Dermatol Clin. 1996; 14:163-9. [PubMed 8821170]
357. Hay RJ. Dermatophytosis and other superficial mycoses. In: Mandel GL, Douglas RG Jr, Bennett JE, eds. Principles and practices of infectious disease. 4th ed. New York: Churchill Livingston; 1995: 2375-86.
358. Drake LA, Dincehart SM, Farmer ER et al. Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. J Am Acad Dermatol. 1996; 34:282-6. [IDIS 363962] [PubMed 8642094]
359. Elewski B. Tinea capitis. Dermatol Clin. 1996; 14:23-31. [PubMed 8821154]
360. Crissey JT. Common dermatophyte infections: a simple diagnostic test and current management. Postgrad Med. 1998; 103:191-205. [IDIS 401902] [PubMed 9479316]
361. Hoeschele JD, Roy AK, Pecoraro VL et al. In vitro analysis of the interaction between sucralfate and ketoconazole. Antimicrob Agents Chemother. 1994; 38:319-25. [PubMed 7910723]
362. Carver PL, Berardi RR, Knapp MJ et al. In vivo interaction of ketoconazole and sucralfate in healthy volunteers. Antimicrob Agents Chemother. 1994; 38:326-9. [IDIS 326059] [PubMed 7910724]
363. Young C, Burrows R, Katz J et al. Hypercalcaemia in sarcoidosis. Lancet. 1999; 353:374. [IDIS 419826] [PubMed 9950444]
364. Glass AR, Cerletty JM, Elliott W et al. Ketoconazole reduces elevated serum levels of 1,25-dihydroxyvitamin D in hypercalcemic sarcoidosis. J Endocrinol Invest. 1990; 13:407-13. [PubMed 2166103]
365. Bia MJ, Insogna K. Treatment of sarcoidosis-associated hypercalcemia with ketoconazole. Am J Kidney Dis. 1991; 18:702-5. [PubMed 1962657]
366. Adams JS, Sharma OP, Diz MM et al. Ketoconazole decreases the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia. J Clin Endocrinol Metab. 1990; 70:1090-5. [IDIS 285913] [PubMed 2318934]
367. Saggese G, Bertelloni S, Baroncelli GI et al. Ketoconazole decreases the serum ionized calcium and 1,25-dihydroxyvitamin D levels in tuberculosis-associated hypercalcemia. Am J Dis Child. 1993; 147:270-3. [IDIS 310648] [PubMed 8438806]
368. Sella A, Kilbourn R, Amato R et al. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol. 1994; 12:683-8. [IDIS 328740] [PubMed 7512126]
369. Ellerhorst JA, Tu SM, Amato RJ et al. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res. 1997; 3:2371-6. [IDIS 398921] [PubMed 9815636]
370. Venturoli S, Marescalchi O, Colombo FM et al. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab. 1999; 84:1304-10. [IDIS 427763] [PubMed 10199771]
371. Chapman SW, Rogers PD, Rinaldi MG et al. Susceptibilities of clinical and laboratory isolates of Blastomyces dermatitidis to ketoconazole, itraconazole, and fluconazole. Antimicrob Agents Chemother. 1998; 42:978-80. [IDIS 403759] [PubMed 9559827]
372. Paterson DL, Singh N. Interactions between tacrolimus and antimicrobial agents. Clin Infect Dis. 1997; 25:1430-40. [IDIS 398457] [PubMed 9431391]
373. Hoban DJ, Zhanel GG, Karlowsky JA. In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients. Antimicrob Agents Chemother. 1999; 43:1463-4. [PubMed 10348771]
374. Aguilar C, Pujol I, Guarro J. In vitro antifungal susceptibilities of Scopulariopsis isolates. Antimicrob Agents Chemother. 1999; 43:1520-2. [IDIS 426263] [PubMed 10348787]
376. Warrington JS, Shader RI, Von Moktke LL et al. In vitro biotransformation of sildenafil (viagra): identification of human cytochromes and potential drug interactions. Drug Metab Dispos. 2000; 28:392-7. [PubMed 10725306]
378. Eli Lilly and Company. Cialis (tadalafil) tablets prescribing information. Indianapolis, IN; 2013 Oct.
379. GlaxoSmithKline. Levitra (vardenafil HCL) tablets prescribing information. Research Triangle Park, NC; 2013 Aug.
380. Lewis-Hall FC. Dear healthcare professional: changes to labeling for Desyrel (trazodone hydrochloride) tablets. Princeton, NJ: Bristol-Myers Squibb Company; 2004. From the FDA website.
381. Zalma A, von Moltke LL, Granda BW et al. In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. Biol Psychiatry. 2000; 47:655-61. [PubMed 10745059]
384. Teva Pharmaceuticals USA Inc. Ketoconazole tablets prescribing information. Sellersville, PA; 2013 Aug.
387. Ortho-McNeil-Janssen Pharmaceuticals. Sporanox (itraconazole) capsules prescribing information. Titusville, NJ: 2009 Nov.
389. Sar B, Boy S, Keo C et al. In vitro antifungal-drug susceptibilities of mycelial and yeast forms of Penicillium marneffei isolates in Cambodia. J Clin Microbiol. 2006; 44:4208-10. [PubMed 16971649]
390. Imwidthaya P, Thipsuvan K, Chaiprasert A et al. Penicillium marneffei: types and drug susceptibility. Mycopathologia. 2001; 149:109-15. [PubMed 11307592]
392. Nguyen M, Boutignon H, Mallet E et al. Infantile hypercalcemia and hypercalciuria: new insights into a vitamin D-dependent mechanism and response to ketoconazole treatment. J Pediatr. 2010; 157:296-302. [PubMed 20394945]
393. Sharma OP. Hypercalcemia in granulomatous disorders: a clinical review. Curr Opin Pulm Med. 2000; 6:442-7. [PubMed 10958237]
394. Conron M, Beynon HL. Ketoconazole for the treatment of refractory hypercalcemic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2000; 17:277-80. [PubMed 11033844]
395. Conron M, Young C, Beynon HL. Calcium metabolism in sarcoidosis and its clinical implications. Rheumatology (Oxford). 2000; 39:707-13. [PubMed 10908687]
424. Chapman SW, Dismukes WE, Proia LA et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis. 2008; 46:1801-12. [PubMed 18462107]
425. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48:503-35. [PubMed 19191635]
426. Galgiani JN, Ampel NM, Blair JE et al. Coccidioidomycosis. Clin Infect Dis. 2005; 41:1217-23. [PubMed 16206093]
427. Perfect JR, Dismukes WE, Dromer F et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010; 50:291-322. [PubMed 20047480]
428. Wheat LJ, Freifeld AG, Kleiman MB et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007; 45:807-25. [PubMed 17806045]
429. Kauffman CA, Bustamante B, Chapman SW et al. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007; 45:1255-65. [PubMed 17968818]
436. . Antifungal drugs. Treat Guidel Med Lett. 2012; 10:61-8; quiz 69-70. [PubMed 22825657]
440. Panel on Opportunistic Infections in HIV-infected Adults and Adolescents. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America (May 7, 2013). Updates may be available at HHS AIDS Information (AIDSinfo) website.
441. Panel on Opportunistic Infection in HIV-exposed and HIV-infected children, US Department of Health and Human Services (HHS). Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics (Nov 6, 2013). Updates may be available at HHS AIDS Information (AIDSinfo) website.
442. Anon. Drugs for parasitic infections. Treat Guidel Med Lett. 2010; 8 (suppl). From the Medical Letter website.
443. Vertex Pharmaceuticals Incorporated. Incivek (telaprevir) film-coated tablets prescribing information. Cambridge, MA; 2013 Apr.
444. Merck & Co. Victrelis (boceprevir) capsules prescribing information. Whitehouse Station, NJ; 2013 Feb.
445. Pfizer Laboratories. Viagra (sildenafil citrate) tablets prescribing information. New York, NY; 2010 Jan.
446. Teva Pharmaceuticals. Mefloquine hydrochloride tablets prescribing information. Sellersville, Pa; 2013 Jun.
447. AR Scientific, Inc. Qualaquin (quinine sulfate) capsules, USP for oral use prescribing information. Philadelphia, PA; 2011 Apr.
448. Novartis Pharmaceutics Corporation. Coartem (artemether/lumefantrine) tablets prescribing information. East Hanover, NJ; 2013 Apr.
a. AHFS Drug Information 2010. McEvoy GK, ed. Ketoconazole. Bethesda, MD: American Society of Health-System Pharmacists; 2010:533-8.